Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration said on Friday.

Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity ...

On Friday, shares of Hims&Hers Health Inc (NYSE:HIMS) dropped over 20% following an FDA announcement that the supply shortage of Novo Nordisk (NYSE:NVO)'s weight loss and diabetes drugs was ending.

The Food and Drug Administration said on Friday that the shortage of semaglutide injection products, such as Novo Nordisk's Wegovy, has been resolved. FDA's update led to renewed uncertainty for a ...

The FDA said the shortage of Novo Nordisk's weight-loss drugs Wegovy and Ozempic is resolved. The move could limit cheaper compounded versions ...

Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...

American doctors, who tracked over 37 million people, said the injections put users at higher risk of nonarteritic ischemic ...

More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.

Investors could be overestimating the contribution of Hims & Hers' compounded GLP-1 medications to its top line. Read why I ...

When celebrities reveal their experiences with newer weight-loss drugs, there are upsides and downsides for patients and ...

Novo Nordisk called out suppliers of compounded weight loss drugs following Hims & Hers’ controversial Super Bowl ad.

As demand remains high for GLP-1 drugs, primary care physicians are concerned about the risks of patients using third-party ...